2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Vaccines, Bispecific Antibody Therapy, Checkpoint Inhibitor, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, CMML, Clinical Research, Clinical Trials, Study Population, Human, Adult, Animal Model
PAPER

3258 LSD1 inhibition reduces glycolytic carbon flux and remodels lipid metabolism to enhance mitochondrial apoptotic priming and venetoclax sensitivity in AML

Kanwaldeep Singh, PhD, Emily Hartung2, Anna Dvorkin-Gheva, PhD3, Christina Muhs4, Islam Alshamleh5, Sara Pishyar6, Pradhariny Prabagaran7, Suhrid Banskota8, Michael F. Saikali9, Dina Khalaf10, Alejandro Garcia-Horton11, Ronan Foley12, Brian Leber, MD13, Irwin Walker, MBBS14, Kylie Lepic15, Frank Schnuetgen, PhD16, Nina Kurrle17, Harald Schwalbe18, Hubert Serve, MD19, Maria Kleppe, PhD, RPh20, Ahmed Aman21, David Uehling22, Hugh Rienhoff Jr.23, Gregory R. Steinberg24, Tobias Berg, PhD25
1 Centre for Discovery in Cancer Research, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada, Department of Oncology, McMaster University, Hamilton, Ontario, Canada
2 Centre for Discovery in Cancer Research, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada, Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada
3 Firestone Institute for Respiratory Health, Division of Respirology, Department of Medicine, Hamilton, Ontario, Canada
4 Frankfurt Cancer Institute, Goethe University Frankfurt, Frankfurt, Germany, German Cancer Consortium (DKTK), partner site Frankfurt/Mainz, and German Cancer Research Center (DKFZ), Heidelberg, Germany, Goethe University Frankfurt, University Medicine, Department of Medicine, Hematology/Oncology, Frankfurt, Germany, Institute of Organic Chemistry and Chemical Biology, Center for Biomolecular Magnetic Resonance (BMRZ), Goethe University Frankfurt, Frankfurt, Germany
5 Frankfurt Cancer Institute, Goethe University Frankfurt, Frankfurt, Germany, German Cancer Consortium (DKTK), partner site Frankfurt/Mainz, and German Cancer Research Center (DKFZ), Heidelberg, Germany, Goethe University Frankfurt, University Medicine, Department of Medicine, Hematology/Oncology, Frankfurt, Germany, Institute of Organic Chemistry and Chemical Biology, Center for Biomolecular Magnetic Resonance (BMRZ), Goethe University Frankfurt, Frankfurt, Germany
6 Centre for Discovery in Cancer Research, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada, Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada
7 Centre for Discovery in Cancer Research, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada, Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada
8 Centre for Metabolism, Obesity and Diabetes Research, McMaster University, Hamilton, Ontario, Canada, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
9 Drug Discovery Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada
10 Department of Oncology, McMaster University, Hamilton, Ontario, Canada, Juravinski Cancer Centre, Hamilton Health Sciences, Hamilton, Ontario, Canada
11 Department of Oncology, McMaster University, Hamilton, Ontario, Canada, Juravinski Cancer Centre, Hamilton Health Sciences, Hamilton, Ontario, Canada
12 Department of Oncology, McMaster University, Hamilton, Ontario, Canada, Juravinski Cancer Centre, Hamilton Health Sciences, Hamilton, Ontario, Canada
13 Department of Medicine, McMaster University, Hamilton, Ontario, Canada, Juravinski Cancer Centre, Hamilton Health Sciences, Hamilton, Ontario, Canada
14 Department of Medicine, McMaster University, Hamilton, Ontario, Canada, Juravinski Cancer Centre, Hamilton Health Sciences, Hamilton, Ontario, Canada
15 Department of Oncology, McMaster University, Hamilton, Ontario, Canada, Juravinski Cancer Centre, Hamilton Health Sciences, Hamilton, Ontario, Canada
16 Frankfurt Cancer Institute, Goethe University Frankfurt, Frankfurt, Germany, German Cancer Consortium (DKTK), partner site Frankfurt/Mainz, and German Cancer Research Center (DKFZ), Heidelberg, Germany, Goethe University Frankfurt, University Medicine, Department of Medicine, Hematology/Oncology, Frankfurt, Germany
17 Frankfurt Cancer Institute, Goethe University Frankfurt, Frankfurt, Germany, German Cancer Consortium (DKTK), partner site Frankfurt/Mainz, and German Cancer Research Center (DKFZ), Heidelberg, Germany, Goethe University Frankfurt, University Medicine, Department of Medicine, Hematology/Oncology, Frankfurt, Germany
18 German Cancer Consortium (DKTK), partner site Frankfurt/Mainz, and German Cancer Research Center (DKFZ), Heidelberg, Germany, Goethe University Frankfurt, University Medicine, Department of Medicine, Hematology/Oncology, Frankfurt, Germany, Institute of Organic Chemistry and Chemical Biology, Center for Biomolecular Magnetic Resonance (BMRZ), Goethe University Frankfurt, Frankfurt, Germany
19 Frankfurt Cancer Institute, Goethe University Frankfurt, Frankfurt, Germany, German Cancer Consortium (DKTK), partner site Frankfurt/Mainz, and German Cancer Research Center (DKFZ), Heidelberg, Germany, Goethe University Frankfurt, University Medicine, Department of Medicine, Hematology/Oncology, Frankfurt, Germany
20 Ajax Therapeutics, New York, New York, United States, Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., Rahway, New Jersey, United States
21 Drug Discovery Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada
22 Drug Discovery Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada
23 Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., Rahway, New Jersey, United States, Institute for Further Study, San Francisco, California, United States
24 Centre for Metabolism, Obesity and Diabetes Research, McMaster University, Hamilton, Ontario, Canada, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
25 Centre for Discovery in Cancer Research, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada, Department of Oncology, McMaster University, Hamilton, Ontario, Canada, Escarpment Cancer Research Institute, Hamilton Health Sciences/McMaster University, Hamilton, Ontario, Canada, Juravinski Cancer Centre, Hamilton Health Sciences, Hamilton, Ontario, Canada

Introduction: Acute myeloid leukemia (AML) remains associated with poor outcomes. Although the BCL2 inhibitor venetoclax (VEN) has improved outcomes in older patients, intrinsic and acquired resistance limit response durability. We previously showed that inhibition of lysine-specific demethylase 1 (LSD1) synergizes with VEN by disrupting AML energy metabolism. Here, we investigated how LSD1 inhibition-induced transcriptional and metabolic remodelling enhances VEN-induced metabolic effects and enhances mitochondrial apoptotic priming.

Methods: The LSD1 inhibitor bomedemstat (MRK-3543), which disrupts LSD1–GFI1/GFI1B interactions, and VEN were evaluated alone or combined in 7 AML cell lines, 41 primary samples, including VEN-refractory specimens, and 2 PDX models. T-448 served as a catalytic-selective LSD1 inhibitor that preserves these interactions. Analyses included Annexin V, BH3 profiling, bulk RNA-seq, single-cell RNA/ATAC multiome studies, Seahorse flux, U-¹³C6-glucose tracing, and untargeted lipidomics.

Results: Single-agent sensitivity varied widely among primary AML samples (VEN IC50, 6.3 nM–26 µM; bomedemstat IC50, 12.6 nM–110 µM). Despite this heterogeneity, bomedemstat and VEN were synergistic (most synergistic area [MSA] score >10) in 32/41 (78%) samples, including VEN-refractory specimens. Among synergistic samples, median MSA score was 18.03 (range, 10.08–32.07), and synergy correlated with bomedemstat sensitivity (ρ=0.47, P=0.0017). In monosomy 7 and NPM1-mutated/FLT3-ITD PDX models, combination treatment produced sustained reductions in bone marrow human CD45? cells (all P≤0.02).

To define the underlying mechanism, we first examined mitochondrial apoptosis. In MOLM-13 cells, bomedemstat increased VEN-induced Annexin V positivity from 19.8±0.8% to 46.6±4.7%. BH3 profiling detected increased responses to BIM, BAD, BID, and PUMA peptides 12–24 hours after LSD1 inhibition, preceding apoptosis and demonstrating enhanced mitochondrial apoptotic priming.

Bulk RNAseq and single-cell multiomic analyses linked this priming state to myeloid differentiation, increased inferred GFI1/GFI1B activity, and suppression of glycolytic and lipid-biosynthetic programs. Bomedemstat induced differentiation and reduced basal glycolytic proton efflux (PER) by 45.6% at 1 µM, whereas T-448 did not induce differentiation and reduced PER by only 11.9%. Bomedemstat, but not T-448, also induced time-dependent AMPK activation in MOLM-13 and MV4-11 cells, characterized by increased activating Thr172 and decreased inhibitory Ser485 phosphorylation, along with reduced AKT Ser473 phosphorylation. Together, this indicates that that disruption of LSD1-GFI1/GFI1B association rather than catalytic inhibition alone, was the major driver of the coordinated differentiation, signaling, and metabolic response.

VEN reduced oxygen consumption rate (OCR), consistent with suppressed oxidative phosphorylation, whereas bomedemstat reduced glycolysis and increased the OCR/PER ratio; together, they constrained both energy-producing pathways. U-¹³C6-glucose tracing showed that VEN increased the abundance and glucose-derived labeling of upper-glycolytic intermediates, consistent with increased entry of glucose-derived carbon into glycolysis. Bomedemstat counteracted this apparent compensatory response by reducing the abundance and labeling of lower-glycolytic metabolites and associated products, including lactate and alanine. This restriction of downstream glycolytic carbon flux was accompanied by transcriptional downregulation of ALDOC and PFKFB4, providing a potential molecular basis for the phenotype. Finally, AMPK activation was associated with increased inhibitory ACC phosphorylation and suppression of lipid-biosynthetic pathways. Untargeted lipidomics revealed a broad decrease in lipid abundance with a relative shift from saturated to polyunsaturated fatty acid-containing species after bomedemstat and combination treatment.

Conclusions: Bomedemstat sensitizes genetically diverse AML, including VEN-refractory disease, to VEN by differentiation-associated restriction of downstream glycolytic carbon flux, AMPK activation and lipid remodeling, thereby enhancing mitochondrial apoptotic priming. Inhibiting demethylase activity alone did not induce these effects, strongly suggesting disruption of LSD1-GFI1/GFI1B association as the key mechanism. These findings establish a mechanistic rationale for clinical evaluation of combined LSD1 and BCL2 inhibition in AML.
Kanwaldeep Singh, PhD: No relevant conflicts of interest to declare.